The Federal Trade Commission (FTC) has reached an agreement in principle with U.S. Anesthesia Partners (USAP) to resolve its closely watched antitrust challenge to the company’s acquisition strategy in Texas. The case, originally filed in 2023, alleged that USAP engaged in a decade-long effort to consolidate anesthesiology practices across the state and ultimately gain leverage to increase prices.

While the terms of the settlement have not yet been publicly disclosed, the FTC has stated that the resolution is intended to restore competition in Texas anesthesia markets. Texas anesthesia providers should be on the lookout for opportunities as USAP will likely have to give up a significant portion of its market share as part of the settlement.

The FTC’s Theory: Serial Acquisitions as a Path to Market Power

At the center of the litigation was the FTC’s challenge to USAP’s “roll-up” strategy. USAP acquired large anesthesiology practices throughout Texas, combining them into a single platform that ultimately became the dominant provider in several regions.

The FTC alleged that this systematic consolidation reduced competitive alternatives for hospitals and payors, allowing USAP to negotiate higher reimbursement rates and contributing to increased healthcare costs.

Notably, the agency’s claims focused not on a single transformative transaction, but on the cumulative effect of multiple acquisitions over time – many of which may not have independently triggered traditional antitrust review thresholds.

Settlement Over Trial

Rather than proceeding to trial, the parties agreed to pause litigation while final settlement terms are negotiated and implemented. The FTC has indicated that it will resume litigation if the agreement is not carried out as expected, underscoring that the agency views the settlement as a mechanism to actively restore competitive conditions – not simply resolve the dispute.

USAP, for its part, has denied wrongdoing but opted to settle in order to avoid the cost and disruption of prolonged litigation.

A Broader Signal for Private Equity and Healthcare

The USAP case is one of the most prominent examples of the FTC’s recent focus on healthcare consolidation and private equity-backed platforms. The agency has repeatedly expressed concern that serial acquisitions, particularly in fragmented provider markets, can result in significant competitive harm when viewed in the aggregate.

Although the FTC initially pursued claims against USAP’s private equity sponsor, those claims were ultimately dismissed, highlighting both the agency’s willingness to test new theories and the legal limits of extending liability to investors.

At the same time, the decision to resolve the case through settlement may reflect a more pragmatic enforcement approach, with regulators seeking structural or behavioral remedies rather than extended litigation where possible.

Key Takeaways

• Roll-up strategies remain a priority enforcement area
  The FTC continues to evaluate the cumulative impact of serial acquisitions, even where individual transactions are relatively small.
• Healthcare services markets are under particular scrutiny
  Physician practice consolidation remains a focal point given its potential effect on pricing and patient costs.
• Private equity involvement is still in the crosshairs
  While not always successful, the FTC has shown a willingness to pursue novel theories targeting sponsors.
• Settlement does not mean reduced scrutiny
  The agency has made clear it will enforce compliance and revisit litigation if necessary.

Looking Ahead

The USAP matter reinforces that antitrust risk in healthcare is no longer limited to large, reportable transactions. Companies pursuing growth through acquisition, particularly in physician services, should carefully consider how a series of smaller deals may be viewed collectively by regulators.

The fact the FTC went after physicians rather than third-party payors may be viewed by the cynical among us as evidence that the government is focused more on reducing healthcare costs than unfair competition or one entity having too much power.

As enforcement continues to evolve, this case will likely serve as a key reference point for both deal structuring and antitrust risk assessment in the healthcare sector.